title: [Prevalence status and mutation pattern of H221Y in subtype B' of HIV-1].
abstract: OBJECTIVE
  To explore the prevalence and mutation pattern of H221Y at reverse transcriptase (RT) among the subtype B' of human immunodeficiency virus1 (HIV-1) in antiviral therapy-failure patients.
  
  
  METHODS
  A total of 1363 sequences, comprising of 1205 therapy-failure individuals and 158 therapy-naive individuals, were submitted to the Stanford HIV drug resistance database (SHDB) to analyze the frequency and mutation pattern of H221Y.
  
  
  RESULTS
  The prevalence of mutation H221Y in the therapy-failure population was significantly higher than that of the therapy-naive (6.59% vs 0.60%) (χ(2) = 6.59, P = 0.027). The emergence of H221Y usually accompanied the position mutations of T215, M184, K103 and Y181 of RT, and the pattern of TAMs/H221Y/Y181C/I was common. Frequency of H221Y in the regimen of AZT/ddI/NVP was more popular than the other 4 regimens (14.6% vs 3.5%, 4.9%, 2.3%, 2.6%, all P < 0.01).
  
  
  CONCLUSIONS
  With a unique mutation pattern, H221Y has a low prevalence in the individuals of first-line therapy-failure patients.
authors.affiliation: State Key Laboratory of Pathogen & Biosecurity, Institute of Microbiology & Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
authors.forename: Han-ping
authors.initials: HP
authors.lastname: Li
authors.forename: Wei
authors.initials: W
authors.lastname: Guo
authors.forename: Yong-jian
authors.initials: YJ
authors.lastname: Liu
authors.forename: Zuo-yi
authors.initials: ZY
authors.lastname: Bao
authors.forename: Lin
authors.initials: L
authors.lastname: Li
authors.forename: Dao-min
authors.initials: DM
authors.lastname: Zhuang
authors.forename: Si-yang
authors.initials: SY
authors.lastname: Liu
authors.forename: Xiao-lin
authors.initials: XL
authors.lastname: Wang
authors.forename: Jing-yun
authors.initials: JY
authors.lastname: Li
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000821:virology; D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D005814:Genes, Viral / Q000235:genetics; D005838:Genotype; D015497:HIV-1 / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D055815:Young Adult